We are live on
!
Find out more
RBFC
Roman Butler Fullerton & Co Portfolio holdings
AUM
$364M
1-Year Est. Return
27.64%
This Fund
S&P 500
This Quarter
Est. Return
+10.75%
1 Year Est. Return
+27.64%
3 Year Est. Return
+108.65%
5 Year Est. Return
+154.92%
10 Year Est. Return
–
AUM
$218M
AUM Growth
+$16.9M
(+8.4%)
Cap. Flow
-$5.93M
Cap. Flow
% of AUM
-2.72%
Top 10 Holdings %
Top 10 Hldgs %
29.73%
Holding
203
New
14
Increased
97
Reduced
60
Closed
16
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Invesco QQQ Trust
QQQ
|
+$1.66M |
| 2 |
Aehr Test Systems
AEHR
|
+$1.14M |
| 3 |
Amphastar Pharmaceuticals
AMPH
|
+$1.1M |
| 4 |
iShares Semiconductor ETF
SOXX
|
+$845K |
| 5 |
Salesforce
CRM
|
+$834K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$1.96M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
+$1.22M |
| 3 |
Ulta Beauty
ULTA
|
+$1.06M |
| 4 |
PXD
Pioneer Natural Resource Co.
PXD
|
+$1.05M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
+$1.04M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 24.11% |
| 2 | Healthcare | 10.23% |
| 3 | Financials | 8.45% |
| 4 | Consumer Discretionary | 6.77% |
| 5 | Consumer Staples | 6.16% |
Similar funds
EW
ACM
RGC
MA
VBFP
DCP
SWA
VIA
Roman Butler Fullerton & Co's Q2 2023 Portfolio in Review
As of Q2 2023, Roman Butler Fullerton & Co held 203 positions worth $218M, up 8.4% from $201M the previous quarter. Its ten largest holdings account for 30% of the portfolio.
Roman Butler Fullerton & Co's Q2 2023 filing shows 14 new, 97 increased, 60 reduced and 16 closed positions. Its largest new stake was Aehr Test Systems: 34,627 shares worth $1.71M. The largest sale was Microsoft, an estimated $1.96M.
By sector, the portfolio is most concentrated in Technology at 24% of assets, up from 20% a quarter earlier, followed by Healthcare and Financials.
- Roman Butler Fullerton & Co's largest Q2 2023 buy was Aehr Test Systems: 34,627 shares worth $1.71M.
- Roman Butler Fullerton & Co added most to Invesco QQQ Trust in Q2 2023, an estimated $1.66M increase.
- Roman Butler Fullerton & Co's biggest Q2 2023 reduction was Microsoft, cutting an estimated $1.96M.
- Roman Butler Fullerton & Co fully exited Regeneron Pharmaceuticals in Q2 2023, selling an estimated $1.22M.
- Roman Butler Fullerton & Co's ten largest holdings make up 30% of its $218M portfolio in Q2 2023.
- Roman Butler Fullerton & Co opened 14 new positions and closed 16 in Q2 2023.
- Roman Butler Fullerton & Co's portfolio value rose 8.4% quarter-over-quarter to $218M.
Based on Roman Butler Fullerton & Co's 13F filing for Q2 2023, filed 25 Jul 2023.